Bojan Vrtovec
Overview
Explore the profile of Bojan Vrtovec including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
106
Citations
1334
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Qayyum A, Frljak S, Juhl M, Poglajen G, Zemljicl G, Cerar A, et al.
ESC Heart Fail
. 2024 Jul;
11(6):3882-3891.
PMID: 39039797
Aims: Allogeneic stem cell therapy is more logistically suitable compared with autologous cell therapy for large-scale patient treatment. We aim to investigate the clinical safety and efficacy profile of the...
2.
Polzl G, Altenberger J, Comin-Colet J, Delgado J, Fedele F, Garcia-Gonzalez M, et al.
Eur J Heart Fail
. 2023 Aug;
25(11):2007-2017.
PMID: 37634941
Aim: The LeoDOR trial explored the efficacy and safety of intermittent levosimendan therapy in the vulnerable phase following a hospitalization for acute heart failure (HF). Methods And Results: In this...
3.
Qayyum A, van Klarenbosch B, Frljak S, Cerar A, Poglajen G, Traxler-Weidenauer D, et al.
Eur J Heart Fail
. 2023 Jan;
25(4):576-587.
PMID: 36644821
Aims: The aim of the SCIENCE trial was to investigate whether a single treatment with direct intramyocardial injections of adipose tissue-derived mesenchymal stromal cells (CSCC_ASCs) was safe and improved cardiac...
4.
Banovic M, Poglajen G, Vrtovec B, Ristic A
J Cardiovasc Dev Dis
. 2022 Dec;
9(12).
PMID: 36547426
It has now been almost 20 years since first clinical trials of stem cell therapy for heart repair were initiated. While initial preclinical data were promising and suggested that stem...
5.
Butt J, Dewan P, Jhund P, Anand I, Atar D, Ge J, et al.
J Am Coll Cardiol
. 2022 Sep;
80(12):1130-1143.
PMID: 36050227
Background: Frailty is an increasingly common problem, and frail patients are less likely to receive new pharmacologic therapies because the risk-benefit profile is perceived to be less favorable than in...
6.
Ugovsek S, Rehberger Likozar A, Finderle S, Poglajen G, Okrajsek R, Vrtovec B, et al.
J Cardiovasc Dev Dis
. 2022 Aug;
9(8).
PMID: 36005445
Patients with advanced heart failure (HF) have reduced cardiac output and impaired peripheral blood flow, which diminishes endothelial shear stress and consequently flow-mediated dilatation (FMD). The aim of our study...
7.
Vrtovec B, Frljak S, Poglajen G, Zemljic G, Cerar A, Sever M, et al.
Eur J Heart Fail
. 2022 Jul;
24(8):1441-1449.
PMID: 35775390
Aims: We investigated the effects of CD34 cell therapy in patients with heart failure with preserved ejection fraction (HFpEF). Methods And Results: In a prospective pilot study, we enrolled 30...
8.
Frljak S, Poglajen G, Vrtovec B
Card Fail Rev
. 2022 Apr;
8:e08.
PMID: 35399548
Heart failure with preserved ejection fraction (HFpEF) is the most common cause of hospitalisation for heart failure. However, only limited effective treatments are available. Recent evidence suggests that HFpEF may...
9.
Zorz N, Poglajen G, Frljak S, Knezevic I, Vrtovec B
Cell Transplant
. 2022 Mar;
31:9636897221080384.
PMID: 35320035
We investigated the effects of cell therapy on local mechanical dyssynchrony (LMD) in patients with nonischemic dilated cardiomyopathy (NICM). We analyzed electromechanical data of 30 NICM patients undergoing CD34 cell...
10.
Seferovic P, Polovina M, Adlbrecht C, Belohlavek J, Chioncel O, Goncalvesova E, et al.
Eur J Heart Fail
. 2021 Nov;
23(12):1999-2007.
PMID: 34755422
Guideline-directed medical therapy (GDMT) has the potential to reduce the risks of mortality and hospitalisation in patients with heart failure (HF) with reduced ejection fraction (HFrEF). However, real-world data indicate...